Sign In
Buy PTCT
$81.33
-3.52 (-4.15%)
At Close: Jul 13, 2026
Reasons Why Investors Should Consider Betting on PTC Stock Now
03:16pm, Friday, 10'th Jul 2026
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
Stocks Look Shaky, But This Sector is Booming (Biotech)
02:06pm, Thursday, 09'th Jul 2026
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 08'th Jul 2026
PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
10:36am, Thursday, 02'nd Jul 2026
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
09:21am, Thursday, 18'th Jun 2026
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incre
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 17'th Jun 2026
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 1
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
12:00am, Tuesday, 16'th Jun 2026
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
11:14pm, Monday, 15'th Jun 2026
– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity – – Offering made at 0% interest with conversion price of $107.48
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
07:00am, Monday, 15'th Jun 2026
– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offering to include buyback of common stock – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Th
PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:12pm, Tuesday, 09'th Jun 2026
PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:01pm, Tuesday, 12'th May 2026
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage
11:21pm, Saturday, 09'th May 2026
PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD fran
PTC Therapeutics Q1 Earnings Call Highlights
05:08pm, Friday, 08'th May 2026
PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or P
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
01:51am, Friday, 08'th May 2026
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
07:30pm, Thursday, 07'th May 2026
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics
